This Evidence Update is based on a recently updated review of research, which includes 135 research studies completed between January 1989 and April 2016. The federal Agency for Healthcare Research and Quality performed the review. The full report updates an earlier version published in February 2012. It can be found at: https://effectivehealthcare. ahrq.gov/topics/antipsychoticschildren-update/research-2017.
NOTE: This Evidence Update looks specifically at evidence related to antipsychotic use for children diagnosed with ADHD and disruptive disorders; it does not report on other approved and off-label antipsychotic use.
1. Pillay J, Boylan K, Carrey N, et al. Firstand Second-Generation Antipsychotics in Children and Young Adults: Systematic Review Update. Prepared by the University of Alberta Evidence Based Practice Center. Agency for Healthcare Research and Quality; March 2017. Errata January 2018.
2. Crystal S, Mackie T, Fenton MC, et al. Rapid Growth of Antipsychotic Prescriptions for Children Who Are Publicly Insured Has Ceased, But Concerns Remain. Health Affairs. 2016;35(6):974-82.
The information in this publication is not intended to be a substitute for professional medical advice.